Invests in
Locations:
Min Investment:
$10,000,000.00Max Investment:
$50,000,000.00Target Investment:
$25,000,000.00
Skills
Education
Master of Business Administration (M.B.A.)
Doctor of Medicine (M.D.)
Bachelor of Science - BS, Summa Cum Laude
Lists including Priscilla
Work Experience
2020
Principal
2020
Vivo Capital is a $7B AUM healthcare-focused investment firm. We are currently investing out of 3 vehicles: our flagship fund IX (late-stage VC, growth, PE) of $1.6B, Innovation Fund II (VC) of ~$330M, and opportunity fund (long-only public vehicle) of $~700M.
2022
Board Member
2022
Board Member
2024
Board Observer
2023
2021
Board Observer
2021
Board Observer
2022
Board Observer
2021
2020 - 2021
Board Observer
2020 - 2021
2018 - 2020
Board Observer
2018 - 2020
2017 - 2020
Assistant Vice President
2017 - 2020
CBC Group (fka C-Bridge Capital) is a healthcare-dedicated private equity firm with $4.7B of AUM focused on platform-building and buyout investment opportunities across three core areas: biopharma, medtech, and healthcare services. Its flagship strategy features an operationally intensive approach. Its representative investment, includes: I-Mab Biopharma (NASDAQ: IMAB), Everest Medicines (HKEX:1952.HK), among others. CBC also manages a complementary private credit strategy (Royalty Bridge Fund/RBF) dedicated to provide alternative non-dilutive financing to healthcare companies backed by royalties, revenue interest, and other cash flows generated by the sale of healthcare products and services. I was involved in the fund creation, strategy, fundraising, and initial capital deployment. Deals and boards involvement includes (but not limited to): - Everest Medicines (HKEX:1952.HK)- company creation/Series A and Series B. Board observer - AffaMed Therapeutics (Private)- company creation/ JV turned to licensing agreement with Samsung Bioepis/Series A and merger with EverInsight. Board observer - Graybug Vision (NASDAQ: GRAY)- $80M crossover. Boad observer - Paratek (NASDAQ: PRTK)- $60M royalty/credit deal